Literature DB >> 16584284

Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Aida Bustad1, Dimiter Terziivanov, Robert Leary, Ruediger Port, Alan Schumitzky, Roger Jelliffe.   

Abstract

BACKGROUND AND OBJECTIVES: This study examined parametric and nonparametric population modelling methods in three different analyses. The first analysis was of a real, although small, clinical dataset from 17 patients receiving intramuscular amikacin. The second analysis was of a Monte Carlo simulation study in which the populations ranged from 25 to 800 subjects, the model parameter distributions were Gaussian and all the simulated parameter values of the subjects were exactly known prior to the analysis. The third analysis was again of a Monte Carlo study in which the exactly known population sample consisted of a unimodal Gaussian distribution for the apparent volume of distribution (V(d)), but a bimodal distribution for the elimination rate constant (k(e)), simulating rapid and slow eliminators of a drug.
METHODS: For the clinical dataset, the parametric iterative two-stage Bayesian (IT2B) approach, with the first-order conditional estimation (FOCE) approximation calculation of the conditional likelihoods, was used together with the nonparametric expectation-maximisation (NPEM) and nonparametric adaptive grid (NPAG) approaches, both of which use exact computations of the likelihood. For the first Monte Carlo simulation study, these programs were also used. A one-compartment model with unimodal Gaussian parameters V(d) and k(e) was employed, with a simulated intravenous bolus dose and two simulated serum concentrations per subject. In addition, a newer parametric expectation-maximisation (PEM) program with a Faure low discrepancy computation of the conditional likelihoods, as well as nonlinear mixed-effects modelling software (NONMEM), both the first-order (FO) and the FOCE versions, were used. For the second Monte Carlo study, a one-compartment model with an intravenous bolus dose was again used, with five simulated serum samples obtained from early to late after dosing. A unimodal distribution for V(d) and a bimodal distribution for k(e) were chosen to simulate two subpopulations of 'fast' and 'slow' metabolisers of a drug. NPEM results were compared with that of a unimodal parametric joint density having the true population parameter means and covariance.
RESULTS: For the clinical dataset, the interindividual parameter percent coefficients of variation (CV%) were smallest with IT2B, suggesting less diversity in the population parameter distributions. However, the exact likelihood of the results was also smaller with IT2B, and was 14 logs greater with NPEM and NPAG, both of which found a greater and more likely diversity in the population studied. For the first Monte Carlo dataset, NPAG and PEM, both using accurate likelihood computations, showed statistical consistency. Consistency means that the more subjects studied, the closer the estimated parameter values approach the true values. NONMEM FOCE and NONMEM FO, as well as the IT2B FOCE methods, do not have this guarantee. Results obtained by IT2B FOCE, for example, often strayed visibly away from the true values as more subjects were studied. Furthermore, with respect to statistical efficiency (precision of parameter estimates), NPAG and PEM had good efficiency and precise parameter estimates, while precision suffered with NONMEM FOCE and IT2B FOCE, and severely so with NONMEM FO. For the second Monte Carlo dataset, NPEM closely approximated the true bimodal population joint density, while an exact parametric representation of an assumed joint unimodal density having the true population means, standard deviations and correlation gave a totally different picture.
CONCLUSIONS: The smaller population interindividual CV% estimates with IT2B on the clinical dataset are probably the result of assuming Gaussian parameter distributions and/or of using the FOCE approximation. NPEM and NPAG, having no constraints on the shape of the population parameter distributions, and which compute the likelihood exactly and estimate parameter values with greater precision, detected the more likely greater diversity in the parameter values in the population studied. In the first Monte Carlo study, NPAG and PEM had more precise parameter estimates than either IT2B FOCE or NONMEM FOCE, as well as much more precise estimates than NONMEM FO. In the second Monte Carlo study, NPEM easily detected the bimodal parameter distribution at this initial step without requiring any further information. Population modelling methods using exact or accurate computations have more precise parameter estimation, better stochastic convergence properties and are, very importantly, statistically consistent. Nonparametric methods are better than parametric methods at analysing populations having unanticipated non-Gaussian or multimodal parameter distributions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584284     DOI: 10.2165/00003088-200645040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  11 in total

1.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Design of dosage regimens: a multiple model stochastic control approach.

Authors:  D S Bayard; M H Milman; A Schumitzky
Journal:  Int J Biomed Comput       Date:  1994-06

3.  Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients.

Authors:  P Maire; X Barbaut; P Girard; A Mallet; R W Jelliffe; T Berod
Journal:  Int J Biomed Comput       Date:  1994-06

4.  Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach.

Authors:  N Taright; F Mentré; A Mallet; R Jouvent
Journal:  Ther Drug Monit       Date:  1994-06       Impact factor: 3.681

5.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 6.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

7.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

8.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

10.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Authors:  L B Sheiner
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

View more
  37 in total

1.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

2.  Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

Authors:  Markus Joerger; Andrés J M Ferreri; Stephan Krähenbühl; Jan H M Schellens; Thomas Cerny; Emanuele Zucca; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

3.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

4.  Parametric and nonparametric population methods.

Authors:  Johannes H Proost; Douglas J Eleveld
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.

Authors:  Johannes H Proost; Douglas J Eleveld
Journal:  Pharm Res       Date:  2006-11-07       Impact factor: 4.200

6.  Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Authors:  Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

7.  Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools.

Authors:  Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

8.  Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Authors:  Paul G Baverel; Radojka M Savic; Justin J Wilkins; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-07-02       Impact factor: 2.745

9.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

10.  Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

Authors:  Anthony M Nicasio; Robert E Ariano; Sheryl A Zelenitsky; Aryun Kim; Jared L Crandon; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.